![Page 1: Use of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program 1 Kenneth J Rothman On behalf of Menno V Huisman, Gregory Y.H](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e675503460f94b62c6e/html5/thumbnails/1.jpg)
Use of Propensity Scores to Assess Comparability of Treatment Groups
in a Registry Program
1
![Page 2: Use of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program 1 Kenneth J Rothman On behalf of Menno V Huisman, Gregory Y.H](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e675503460f94b62c6e/html5/thumbnails/2.jpg)
Disclosure Information
Kenneth J Rothman is an employee of RTI Health Solutions, an independent non-profit research organization that does work for government agencies and pharmaceutical companies.
GLORIA-AF is sponsored by Boehringer Ingelheim
2
![Page 3: Use of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program 1 Kenneth J Rothman On behalf of Menno V Huisman, Gregory Y.H](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e675503460f94b62c6e/html5/thumbnails/3.jpg)
GLORIA-AF
3
GLORIA-AF is a large, international, observational registry program of patients with newly diagnosed AF at risk of stroke
Study objectives:1. Characterize patients in various regions of
the world newly diagnosed with non-valvular AF at risk for stroke
2. Describe current patterns of antithrombotic treatment
3. Assess effectiveness and safety of antithrombotic treatments
![Page 4: Use of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program 1 Kenneth J Rothman On behalf of Menno V Huisman, Gregory Y.H](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e675503460f94b62c6e/html5/thumbnails/4.jpg)
Design of GLORIA-AF
4
Patients on dabigatran etexilate
Baseline Visit
Phase ICross-sectional
All patients
Phase IICross-sectional, longitudinal follow-up of dabigatran patients
Phase IIICross-sectional, longitudinal follow-up of all patients
Baseline VisitBaseline Visit
Status:Start after comparability assessment of treatment groups in Phase II
Status:Currently ongoing
Status:Ended Jan 2013
![Page 5: Use of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program 1 Kenneth J Rothman On behalf of Menno V Huisman, Gregory Y.H](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e675503460f94b62c6e/html5/thumbnails/5.jpg)
Methods in GLORIA-AF
• In Phase II and III Propensity Score (PS) techniques will be used to assess comparability of the treatment groups (dabigatran compared with VKA). Specifically, we measure the proportion of patients within the range of overlapping PS.
5
Figure: Sebastian Schneeweiss, Jerry Avorn A review of uses of health care utilization databases for epidemiologic research on therapeutics Journal of Clinical Epidemiology Volume 58, Issue 4 2005 323 - 337
![Page 6: Use of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program 1 Kenneth J Rothman On behalf of Menno V Huisman, Gregory Y.H](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e675503460f94b62c6e/html5/thumbnails/6.jpg)
Methods in GLORIA-AF
• The decision to begin Phase III will be primarily based on the degree of overlap of the PS. If 95% or more of patients are in the region of overlapping PS, we will proceed to Phase III for that region.
• Assessment of comparability is made independently in geographic regions. The first assessment occurred in North America.
6
![Page 7: Use of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program 1 Kenneth J Rothman On behalf of Menno V Huisman, Gregory Y.H](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e675503460f94b62c6e/html5/thumbnails/7.jpg)
Results
• From November, 2011 through April, 2013, 1672 eligible patients were enrolled in North America.
• DE was initiated in 536 and VKA in 488 patients.
• 15% of patients were prescribed other Novel Oral Anticoagulants (NOACs), and aspirin in 11%.
• 11% of patients did not receive antithrombotic therapy to prevent ischemic stroke.
![Page 8: Use of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program 1 Kenneth J Rothman On behalf of Menno V Huisman, Gregory Y.H](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e675503460f94b62c6e/html5/thumbnails/8.jpg)
Results
Missing/unknown data were imputed using Naïve Bayes classifier. DE, dabigatran etexilate; VKA, vitamin K antagonist.
DE (N = 536) VKA (N = 488) n (%) n (%)Age class
< 65 years 132 (24.6) 107 (21.9)65 to < 75 years 204 (38.1) 144 (29.5)≥ 75 years 200 (37.3) 237 (48.6)
Gender Male 316 (59.0) 262 (53.7)Female 220 (41.0) 226 (46.3)
HypertensionYes, uncontrolled 43 (8.0) 48 (9.8)Yes, controlled 381 (71.1) 355 (72.7)No 112 (20.9) 85 (17.4)
![Page 9: Use of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program 1 Kenneth J Rothman On behalf of Menno V Huisman, Gregory Y.H](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e675503460f94b62c6e/html5/thumbnails/9.jpg)
Results
Missing/unknown data were imputed using Naïve Bayes classifier. DE, dabigatran etexilate; VKA, vitamin K antagonist.
DE (N = 536) VKA (N = 488) n (%) n (%)Diabetes mellitus
No 411 (76.7) 328 (67.2)Yes 125 (23.3) 160 (32.8)
CHADS2 Score
Low (score=0) 39 (7.3) 23 (4.7)Moderate (score=1) 206 (38.4) 133 (27.3)High (score>=2) 291 (54.3) 332 (68.0)
![Page 10: Use of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program 1 Kenneth J Rothman On behalf of Menno V Huisman, Gregory Y.H](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e675503460f94b62c6e/html5/thumbnails/10.jpg)
Results – Propensity score distribution by treatment group
10
![Page 11: Use of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program 1 Kenneth J Rothman On behalf of Menno V Huisman, Gregory Y.H](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e675503460f94b62c6e/html5/thumbnails/11.jpg)
Results
• The proportion of patients in the overlapping region of the PS between the two treatment groups was 99% when the model contained a pre-specified subset of risk factors for stroke and bleeding.
• In a sensitivity analysis that included all collected baseline characteristics, the overlapping region comprised 96%.
• Either result was sufficient to proceed to the comparative Phase III.
![Page 12: Use of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program 1 Kenneth J Rothman On behalf of Menno V Huisman, Gregory Y.H](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e675503460f94b62c6e/html5/thumbnails/12.jpg)
Conclusions
• Nearly all patients fell within the overlapping range of propensity scores.
• Mostly overlapping PS ranges does not guarantee an absence of confounding. It does, however, allow for control of confounding in the data analysis for those factors that are included in the PS model.
![Page 13: Use of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program 1 Kenneth J Rothman On behalf of Menno V Huisman, Gregory Y.H](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e675503460f94b62c6e/html5/thumbnails/13.jpg)
Back up slides
![Page 14: Use of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program 1 Kenneth J Rothman On behalf of Menno V Huisman, Gregory Y.H](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e675503460f94b62c6e/html5/thumbnails/14.jpg)
Variables in main PS model
Age classGenderHypertensionDiabetes mellitusPrevious strokeTIAnon-CNS arterial embolismCongestive heart failureMIPresence of complex aortic plaques
Peripheral artery diseaseAbnormal kidney functionHepatic diseasePrior bleedingAny drug (HASBLED)Alcohol abuseCoronary artery diseaseSmoking statusPsychosocial factors
![Page 15: Use of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program 1 Kenneth J Rothman On behalf of Menno V Huisman, Gregory Y.H](https://reader036.vdocuments.mx/reader036/viewer/2022062516/56649e675503460f94b62c6e/html5/thumbnails/15.jpg)
Variables included in sensitivity analysis
15